A Comprehensive Study of ImageNet Pre-Training for Historical Document Image Analysis

Automatic analysis of scanned historical documents comprises a wide range of image analysis tasks, which are often challenging for machine learning due to a lack of human-annotated learning samples. With the advent of deep neural networks, a promising way to cope with the lack of training data is to pre-train models on images from a different domain and then fine-tune them on historical documents. In the current research, a typical example of such cross-domain transfer learning is the use of neural networks that have been pre-trained on the ImageNet database for object recognition. It remains a mostly open question whether or not this pre-training helps to analyse historical documents, which have fundamentally different image properties when compared with ImageNet. In this paper, we present a comprehensive empirical survey on the effect of ImageNet pre-training for diverse historical document analysis tasks, including character recognition, style classification, manuscript dating, semantic segmentation, and content-based retrieval. While we obtain mixed results for semantic segmentation at pixel-level, we observe a clear trend across different network architectures that ImageNet pre-training has a positive effect on classification as well as content-based retrieval

Local and global feature aggregation for accurate epithelial cell classification using graph attention mechanisms in histopathology images

In digital pathology, cell-level tissue analyses are widely used to better understand tissue composition and structure. Publicly available datasets and models for cell detection and classification in colorectal cancer exist but lack the differentiation of normal and malignant epithelial cells that are important to perform prior to any downstream cell-based analysis. This classification task is particularly difficult due to the high intra-class variability of neoplastic cells. To tackle this, we present here a new method that uses graph-based node classification to take advantage of both local cell features and global tissue architecture to perform accurate epithelial cell classification. The proposed method demonstrated excellent performance on F1 score (PanNuke: 1.0, TCGA: 0.98) and performed significantly better than conventional computer vision methods (PanNuke: 0.99, TCGA: 0.92)

Self-rule to multi-adapt: Generalized multi-source feature learning using unsupervised domain adaptation for colorectal cancer tissue detection.

Supervised learning is constrained by the availability of labeled data, which are especially expensive to acquire in the field of digital pathology. Making use of open-source data for pre-training or using domain adaptation can be a way to overcome this issue. However, pre-trained networks often fail to generalize to new test domains that are not distributed identically due to tissue stainings, types, and textures variations. Additionally, current domain adaptation methods mainly rely on fully-labeled source datasets. In this work, we propose Self-Rule to Multi-Adapt (SRMA), which takes advantage of self-supervised learning to perform domain adaptation, and removes the necessity of fully-labeled source datasets. SRMA can effectively transfer the discriminative knowledge obtained from a few labeled source domain's data to a new target domain without requiring additional tissue annotations. Our method harnesses both domains' structures by capturing visual similarity with intra-domain and cross-domain self-supervision. Moreover, we present a generalized formulation of our approach that allows the framework to learn from multiple source domains. We show that our proposed method outperforms baselines for domain adaptation of colorectal tissue type classification in single and multi-source settings, and further validate our approach on an in-house clinical cohort. The code and trained models are available open-source: https://github.com/christianabbet/SRA

SEEK (Sludge to Energy Enterprises in Kampala): co-processing faecal sludge for fuel production

The goal of this project was to improve the resource-recovery value of faecal sludge treatment products. A market assessment identified coffee husks, spent grain, and sawdust as optimal organic wastes to coprocess with faecal sludge to increase its fuel value. Drying times of faecal sludge to 90% solids were reduced by half with co-pelletizing with these organic wastes. Briquettes produced with char had comparable heating value, fuel performance, and emissions to charcoal briquettes currently being sold. Use of pellets as a fuel was tested in a gasifier and in several industrial clay kilns (after crushing). High ash content led to clinker formation in the gasifier, but performed well in kilns. The potential market for co-processed faecal sludge fuels is high in Kampala, Uganda, especially among industries, however, the market for pellets needs to be developed

Business model analysis of low-cost carriers on the exaple of Ryanair

nicht vorhande

Pyruvate kinases have an intrinsic and conserved decarboxylase activity

The phosphotransfer mechanism of pyruvate kinases (PYKs) has been studied in detail, but the mechanism of the intrinsic decarboxylase reaction catalysed by PYKs is still unknown. 1H NMR was used in this work to follow oxaloacetate (OAA) decarboxylation by trypanosomatid and human PYKs confirming that the decarboxylase activity is conserved across distantly related species. Crystal structures of Trypanosoma brucei PYK (TbPYK) complexed with the product of the decarboxylase reaction (pyruvate), and a series of substrate analogues (D-malate, α-ketoglutarate and oxalate) show that the OAA analogues bind to the kinase active site with similar binding modes, confirming that both decarboxylase and kinase activities share a common site for substrate binding and catalysis. Decarboxylation of OAA as monitored by NMR for TbPYK is relatively slow with turn-over values of 0.86 s-1 and 1.47 s-1 in the absence and presence of fructose 2,6-bisphosphate (F26BP), respectively. Human M1PYK has a measured turn-over value of 0.50 s-1. The X-ray structures explain why the decarboxylation activity is specific for OAA and is not general for α-keto acid analogues. Conservation of the decarboxylase reaction across divergent species is a consequence of piggybacking on the conserved kinase mechanism which requires a stabilised enol intermediate

Proceedings of the 13th annual conference of INEBRIA

CITATION: Watson, R., et al. 2016. Proceedings of the 13th annual conference of INEBRIA. Addiction Science & Clinical Practice, 11:13, doi:10.1186/s13722-016-0062-9.The original publication is available at https://ascpjournal.biomedcentral.comENGLISH SUMMARY : Meeting abstracts.https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-016-0062-9Publisher's versio

The SIB Swiss Institute of Bioinformatics' resources: focus on curated databases

The SIB Swiss Institute of Bioinformatics (www.isb-sib.ch) provides world-class bioinformatics databases, software tools, services and training to the international life science community in academia and industry. These solutions allow life scientists to turn the exponentially growing amount of data into knowledge. Here, we provide an overview of SIB's resources and competence areas, with a strong focus on curated databases and SIB's most popular and widely used resources. In particular, SIB's Bioinformatics resource portal ExPASy features over 150 resources, including UniProtKB/Swiss-Prot, ENZYME, PROSITE, neXtProt, STRING, UniCarbKB, SugarBindDB, SwissRegulon, EPD, arrayMap, Bgee, SWISS-MODEL Repository, OMA, OrthoDB and other databases, which are briefly described in this article

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570